HNHiroshi Nemoto

Hiroshi Nemoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroshi Nemoto has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alpha-Fetoprotein-Producing Cancer That Derived in Barrett’s Esophageal Cancer after Chemotherapy

    by Kazuaki Yokomizo, Hiroshi Nemoto, Genshu Tate, Kazuma Sakuraba, Taketo Matsubara, Junichi Tanaka

    我々は下部食道癌に対し化学療法を施行した後,その一部より短期間に発生したAFP産生癌というまれな1例を経験した.また,新規幹細胞マーカーSal-like protein 4(以下,SALL4と略記)染色がAFPと解離していたことも大変興味深い.食道におけるAFP産生癌は本例を含め22例目であり,この領域のAFP産生癌の発症については,Barrett食道→食道腺癌→AFP産生癌のシークエンスが推察された.症例は64歳の男性で,食道癌(LtAe,2型,cStage III)と診断した.術前化学療法が奏効したが,5コース終了後に病巣部の下端にtype 1の腫瘤が発生した.手術標本では下部食道に2型癌と,胃側に赤色の1型癌を認めた.両病変は腺癌であったが,1型部分はAFP染色陽性であった.また,SALL4染色では1型部分はAFPと一致し陽性だが,AFP陰性であった口側の領域にも陽性部分があった.

    • 1 July 2014
      • Vol. 41  (7) , 909-12

    [A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].

    by Hiroshi Nemoto, Genshu Tate, Takahiro Umemoto, Taketo Matsubara, Hiroki Mizukami, Mitsuo Saito, Gaku Kigawa, Akihiko Matsumiya, Junichi Tanaka

    A 69-year-old man was diagnosed with advanced esophageal cancer(well-differentiated squamous cell carcinoma). Neoadjuvant chemotherapy consisting of nedaplatin and 5-fluorouracil(5-FU)was initiated. After two courses of chemotherapy, the patient was judged to have achieved a clinical complete response. The patient then decided against undergoing surgery and opted instead to continue with the chemotherapy, receiving five courses in total. However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011. Squamous cell carcinoma with an adenocarcinoma component, which consisted of poorly differentiated squamous cell carcinoma and tubular adenocarcinoma cells, was observed at the primary site. Metastasis of the cancer to the liver was detected 2 months after surgery. The subsequent administration of four courses of docetaxel to the patient did not result in any beneficial effects, and the patient developed carcinomatous pleurisy and died of this complication in November 2011. The patient survived for a total of 21 months after starting chemotherapy. In this case, the chemotherapy itself may have resulted in the dedifferentiation of a well differentiated squamous cell carcinoma to result in a poorly differentiated squamous cell carcinoma with an adenocarcinoma component.


    • 6 June 2014
      • Vol. 61  (130) , 354-6

    p16 Methylation is frequently detected in the serum of metastatic colorectal cancer patients.

    by Kenji Hibi, Hiroki Mizukami, Mitsuo Saito, Gaku Kigawa, Hiroshi Nemoto

    For the purpose of detection of colorectal cancers, we tried to detect p16 methylation in the serum of colorectal cancer patients using quantitative methylation-specific polymerase chain reaction (qMSP). Out of 211 serum samples derived from colorectal cancer patients, 14 (7%) exhibited p16 methylation in their serum DNA by qMSP. After completion of qMSP analysis in all specimens, clinicopathological data were correlated with the molecular analysis. Interestingly, a significant difference was observed in the presence of distant metastasis (P = 0.0420). Moreover, a trend was shown toward preferentially developing lymph node metastasis (P = 0.0547), thus suggesting that p16 methylation in serum could be detected more frequently in metastatic colorectal cancer patients. High sensitivity of qMSP makes it possible to detect smaller amounts of tumor DNA in the serum. In principle, the methylation status of a primary tumor is not required in advance to detect circulating tumor DNA, suggesting that qMSP can be used as a screening method for cancer.


  • Methylation of the HACE1 gene is frequently detected in hepatocellular carcinoma.

    by Makiko Sakata, Kazuaki Yokomizo, Yohei Kitamura, Kazuma Sakuraba, Atsushi Shirahata, Tetsuhiro Goto, Hiroki Mizukami, Mitsuo Saito, Kazuyoshi Ishibashi, Gaku Kigawa, et al.

    Recently, it has been reported that HACE1, the E3 ubiquitin ligase, is epigenetically inactivated in human Wilms' tumors and HACE 1 expression was also down-regulated in colorectal and gastric carcinomas. In this study, methylation status of the HACE1 gene was examined in primary carcinomas and the corresponding normal tissues derived from 27 patients with HCC using quantitative methylation-specific PCR (qMSP). Methylation of the HACE1 gene was detected in 18 out of the 27 (67%) HCCs, suggesting that the methylation of HACE1 was frequently observed in HCC. The clinicopathological data were then correlated with these results. In the value of serum AFP (α-fetoprotein), a significant difference was observed (p=0.0025). All stages of HCCs presented HACE1 methylation, indicating that the HACE1 gene has been methylated from the early stages of HCCs.


    • 1 May 2013
      • Vol. 40  (5) , 605-8

    [Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].

    by Hitoshi Soda, Hiroshi Nemoto, Sotaro Akatsuka, Hitoshi Arioka, Ken Shimada, Tomohiro Ito, Yasutaka Takinishi, Mizutomo Egawa, Atsushi Nagashima, Takeshi Kenmochi, et al.

    In July 2008, cetuximab treatment for unresectable advanced or recurrent colorectal cancer was approved in Japan, but there have been few reports on this therapy in Japan. We retrospectively analyzed the efficacy and safety of cetuximab(Cmab)+irinotecan(CPT-11)for unresectable advanced or recurrent colorectal cancer from October 2008 to April 2010 at 5 centers in the Kanagawa region. The number of patients enrolled was 38, all of whom were treated after second-line therapy. The RR was 24%. DCR was 68%. TTF was 105 days and OS was 242 days. At 5 centers, Cmab+CPT-11 was an effective and safe treatment after second-line therapy.

  • Methylation of the UNC5C gene is frequently detected in hepatocellular carcinoma.

    by Masato Sakata, Kazuaki Yokomizo, Yoshifumi Kitamura, Kazuma Sakuraba, Atsushi Shirahata, Takehiko Goto, Hajime Mizukami, Masao Saito, Kenichi Ishibashi, Gaku Kigawa, et al.


  • Methylation of the WNT5A gene is frequently detected in early gastric carcinoma.

    by Kenji Hibi, Makiko Sakata, Kazuaki Yokomizi, Yo-Hei Kitamura, Kazuma Sakuraba, Rnatsushi Shirahata, Tetsuhiro Goto, Hiroki Mizukami, Mitsuo Saito, Kazuyoshi Ishibashi, et al.

    Recently, it has been reported that WNT5A methylation was frequently detected in colorectal cancers. However, the relationship between the WNT5A methylation and the characteristics of gastric cancer remains unknown. Methylation status of the WNT5A gene was examined in primary carcinomas and the corresponding normal tissues derived from 38 patients with gastric cancer using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated. Aberrant methylation of the WNT5A gene was detected in 7 out of the 38 (18%) primary gastric carcinomas, suggesting that the methylation of WNT5A is observed in gastric carcinomas as well as colorectal ones. The clinicopathological data were correlated with the methylation results. A significant difference was observed in the extent of tumor (p=0.0226). Moreover, a trend was shown towards early TNM stages in methylated tumors (p=0.209). WNT5A was more frequently methylated in early gastric carcinomas.


    • 1 October 2012
      • Vol. 32  (10) , 4371-4

    FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis.

    by Kenji Hibi, Hiroki Mizukami, Mitsuo Saito, Gaku Kigawa, Hiroshi Nemoto, Yutaka Sanada

    For the purpose of colorectal cancer detection, we investigated fibrillin-2 (FBN2) methylation in the serum of colorectal cancer patients using quantitative methylation-specific polymerase chain reaction (qMSP). Out of 78 patients with colorectal cancer, 49 (63%) exhibited methylation of FBN2 in their tumor tissue DNA, suggesting that FBN2 methylation frequently exists in colorectal cancer. We next examined the methylation status of FBN2 in the serum DNA of patients with colorectal cancer. Out of 49 serum samples, four (8%) exhibited FBN2 methylation in their serum DNA by qMSP, suggesting that FBN2 methylation exists in the serum of colorectal cancer patients. After completion of qMSP analysis in all specimens, clinicopathological data were correlated with the molecular analysis findings. Interestingly, methylation of FBN2 was found in the serum DNA of male (p=0.0167) patients, and in those with hepatic metastasis (p<0.0001). The clinical sensitivity of this assay can be potentially improved by incorporating other common genetic targets such as p53 and KRAS. Advances in technology which will permit for rapid detection of an array of specific mutations and methylation would enhance the utility of this approach.


    • 1 May 2012
      • Vol. 32  (5) , 1757-62

    Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.

    by Tetsuhiro Goto, Kazuki Shinmura, Kazuaki Yokomizo, Kazuma Sakuraba, Youhei Kitamura, Atsushi Shirahata, Mitsuo Saito, Gaku Kigawa, Hiroshi Nemoto, Yutaka Sanada, et al.

    Predictors of the response of colorectal cancer to chemotherapy remain poorly understood. We analyzed the mRNA expression levels of enzymes related to sensitivity to 5-fluorouracil derivatives in patients with colorectal cancer. Danenberg tumor profile method (DTP) was used in order to measure mRNA expression levels of thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD), and thymidine phosphorylase (TYMP) from 180 patients with colorectal cancer. The relations of expression levels with clinicopathological factors and outcomes were studied. Higher TYMS expression was associated with greater age, DPYD expression with greater age, poorer differentiation and low invasion, and TYMP expression with poorer differentiation and lack of peritoneal metastasis. DPYD expression positively correlated with TYMP expression. In patients with stage IV disease, high DPYD or TYMP expression was associated with poor outcomes. mRNA expression of TYMS, DPYD, and TYMP is associated with distinct characteristics and may be useful for predicting survival in patients with stage IV colorectal cancer.


    • 1 April 2012
      • Vol. 32  (4) , 1319-22

    Methylation of the DFNA5 gene is frequently detected in colorectal cancer.

    by Kazuaki Yokomizo, Yoshikuni Harada, Kazuhiro Kijima, Kazuki Shinmura, Makiko Sakata, Kazuma Sakuraba, Youhei Kitamura, Atsushi Shirahata, Tetsuhiro Goto, Hiroki Mizukami, et al.

    Recently, the human deafness, autosomal dominant 5 gene, DFNA5, has frequently been detected in cancer tissues. The methylation status of the DFNA5 gene in colorectal cancer was examined and was compared to the clinocopathological findings. Eighty-five tumor samples and corresponding normal tissues were obtained from patients with colorectal cancer who underwent surgery at our hospital. The methylation status of the DFNA5 gene in these samples was examined by quantitative methylation-specific PCR (qMSP). Subsequently, the clinicopathological findings were correlated with the methylation status of the DFNA5 gene. DFNA5 gene methylation was found in 29 (34%) out of the 85 colorectal carcinomas, suggesting that it was frequently observed in colorectal cancer. A significant correlation with methylation was observed for lymphatic vessel invasion and TNM stage (p=0.0268 and p=0.0189, respectively). DFNA5 might act as a tumor suppressor gene and DFNA5 gene methylation might play an important role in the development of colorectal cancer. Our data implicate DFNA5 gene methylation as a novel molecular biomarker in colorectal cancer.